

Fresenius Kabi Canada Ltd.

165 Galaxy Blvd, Suite 100 Toronto, Ontario Canada M9W 0C8 T: 905.770.3711 F: 844.513.1522 W: fresenius-kabi.ca

June 15, 2023

Adenosine Injection Allocation Notice

Dear Valued Customer,

Fresenius Kabi Canada would like to advise that our Adenosine Injection 3 mg/mL SD Vial 2 mL, Adenosine Injection 3 mg/mL prefilled syringe 2 mL, and Adenosine Injection 3 mg/mL prefilled syringe 4 mL will be placed on a protective allocation effective immediately. Contract customers are allocated 100% of historical monthly demand.

Please note allocations for the remainder of June 2023 are reflective of 100% historical monthly demand minus volumes already purchased for the month. Beginning July 2023, allocations will be reset to a full month's quantity.

In addition to these allocations, a limited amount of Adenosine will be made available to support the Dipyridamole shortage. We will be working closely with Group Purchasing Organizations (GPOs), local health authorities, and/or provinces to distribute the limited quantities. More information will be made available shortly.

DIN	Fresenius Kabi Product Code	MDP Product Code	McKesson Product Code	Product Description	Allocation Date
02267659	C605102	937071	192880	Adenosine Injection 3 mg/mL SD Vial 2 mL	100% Allocation Jun. 15, 2023
02457474	K051002	970852	115670	Adenosine Injection 3 mg/mL prefilled syringe 2 mL	100% Allocation Jun. 15, 2023
02457482	K051004	970864	115606	Adenosine Injection 3 mg/mL prefilled syringe 4 mL	100% Allocation Jun. 15, 2023

We recognize the difficulties and inconvenience that you may encounter as a result of this allocation, and we thank you for your patience and understanding in this matter.

If you have any questions or concerns, please do not hesitate to contact your sales representative.

Sincerely,

Joseph Le Senior Manager, Commercial Operations & Analytics joseph.le@fresenius-kabi.com